Supporting your choice of surgical therapies for your patients with coronary artery disease (CAD).
Looking for improved outcomes? Consider pump-assisted beating heart (PABH) as an option for your coronary patients. PABH includes the use of cardiopulmonary bypass, without arresting the heart or cross-clamping the aorta to provide hemodynamic support during a beating heart cardiac procedure.
Cardiac surgeons are discovering that pump-assisted beating heart CABG offers better outcomes with specific patients. Data from several clinical studies support these improved outcomes.
While pump-assisted beating heart procedures can be used broadly, clinical evidence demonstrates superior outcomes for:
More than 20 years ago when we introduced the Octopus™ tissue stabilizers for OPCAB, the way cardiac surgeons could perform beating heart surgeries changed. For the first time, epicardial tissue could be stabilized using vacuum-assisted technology to complete anastomoses. Now tissue stabilizers are seen as standard for beating heart therapies and can be paired with CPB to further support the patient during cardiac surgery.1
We continue to offer innovative technologies to help you perform PABH procedures. The Octopus tissue stabilizers, Starfish™ heart positioners, Octobase™ or ThoraTrak™ MICS retractor system, along with our cannulae, and perfusion technologies are just some of the options we offer to help you perform pump-assisted beating heart procedures. See our Therapies and Technologies Guide for more details.
Beating heart cardiac surgery procedures with pump-assist are becoming more mainstream today. As the patient population changes, so do the demands on you, the cardiac surgeon. That’s why Medtronic is committed to supporting beating heart cardiac surgery. Together — with your skilled knowledge and our enabling technologies — we can deliver the right therapies for each individual patient with coronary artery disease (CAD).
Learn new beating heart skills and gain hands-on experience with technologies that may be new to you. We offer a full range of training programs. Contact us to learn more.
Erkut B, Dag O, Kaygin MA, et al. On-pump beating-heart versus conventional coronary artery bypass grafting for revascularization in patients with severe left outcomes. Can J Surg. December 2013;56(6):398–404.
Afrasiabirad A, Safale N, Montazergaem H. On-pump beating heart coronary artery bypass in high risk coronary patients. Iran J Med Sci. January 2015;40(1):40–44.
Chaudhry UA, Harling L, Sepehripour AH, et al. Beating-heart versus conventional on-pump coronary artery bypass grafting: A meta-analysis of clinical outcomes. Ann Thorac Surg. December 2015;100(6):2251–2260.
Al-Sarraf N, Thalib L, Hughes A, et al. Cross-clamp time is an independent predictor of mortality and morbidity in low-and high-risk cardiac patients. Int J Surg. 2011;9(1):104–109.
Key risks of Octopus™ tissue stabilizers include: hematoma, laceration, ischemia, EKG/ECG changes, and abrasions.
Key risks of Starfish™ heart positioners include: tissue damage, infection, dissection, ischemia, laceration, and organ dysfunction.
Key risks of the Octobase™ sternal retractor include: laceration and infection.
Key risks of the ThoraTrak™ MICS retractor system include: infection, laceration, and tissue damage.
Not all patients are candidates for beating heart procedures. Some patients would require cardiopulmonary support during surgery. Caution: Federal law (USA) restricts this device to sale by or on the order of a physician. For a listing of indications, contraindications, precautions, and warnings, please refer to the Instructions for Use.